Global Acute pancreatitis Market - Overview
Acute pancreatitis (AP) is a systemic immune inflammatory response to auto-digestion of the pancreas and peri-pancreatic organs. This condition is common and life threatening disease. With an annual incidence of 4.9–73 cases per 100000 people worldwide. The males are predominantly affected at young ages with a ratio of 2.5:1. The mortality rate for pancreatitis is between 1.5% and 4.2% according to large epidemiological studies, but is a frequent gastrointestinal disease with a morbidity rate of 30% in severe cases.
Regardless of the technological advances in critical care drugs in the course of recent years, the death rate has prevailed to approximately 10%. Acute pancreatitis is confirmed by medical history, physical examination, and typically a blood test (amylase or lipase) for digestive enzymes of the pancreas. The diagnosis of pancreatic is often difficult and treatments are therefore delayed because the organ is relatively inaccessible. The testing of acute pancreatits include techniques such as transabdominal ultrasound, endoscopic ultrasound (EUS), and magnetic resonance cholangiopancreatography (MRCP). Surgery has no role in mild acute pancreatitis or in severe pancreatitis with sterile necrosis. Surgical therapy in infected necrosis can be considered, based on the availability of other therapeutic options and the consistency of the necrotic material.
According to the 2013 American College of Gastroenterology (ACG) guidelines, antibiotics are usually not recommended in patients with acute pancreatitis, regardless of the type or disease severity. Infection must be suspected in patients who have signs of deterioration such as fever, increasing WBC count. Most infections in pancreatic necrosis are caused by single bacterial species from the gut. In patients with infected necrosis, antibiotics known to penetrate pancreatic necrosis, such as carbapenems, fluoroquinolones, and metronidazole, are recommended. Byetta (exanitide) is a drug from Eli Lily and Company that is FDA approved to treat acute pancreatitis.
The global acute pancreatitis market is expected to grow at a CAGR of 3.5% during forecasted period 2017-2023.
Abbott Laboratories (US), McNeil Consumer Healthcare (US), Sun BioPharma, Inc (US), Atox Bio Inc. (Israel), Calcimedica Inc. (US), D-Pharm Ltd (Israel), Dynavax Technologies Corporation (US), Glaxosmithkline Plc (UK) university’s and institutes are also included in the treatment of acute pancreatic like Radboud University, University Medicine Greifswald and others are some of the prominent players at the forefront of competition in the global acute pancreatitis market and are profiled in MRFR Analysis.
Request a Premium Sample Report @
https://www.marketresearchfuture.com/sample_request/1565

Global Acute pancreatitis Market – Regional:
Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
The North America dominated the global acute pancreatitis market with the U.S. holding the largest market share owing to numerous developments in the medical sector, and rising numbers of research institutes for better treatment of this diseases. The reported annual incidence of acute pancreatitis has ranged from 4.9 to 35 per 100,000 population. Acute pancreatitis is the leading gastrointestinal cause of hospitalization in the United States.
In Europe, the market for multiple sclerosis is expected to exhibit positive growth during the forecast period. The incidence of acute pancreatitis varies across Europe with gallstone dominantly spread across southern Europe and alcohol in Eastern Europe. In Western countries, the most common cause is alcohol, accounting for 65 percent of acute pancreatitis cases in the US, 20 percent of cases in Sweden, and 5 percent of those in the United Kingdom. In August, 2014, BSV BioScience GmbH, Germany received orphan designation for ulinastatin by the European Commission for the treatment of acute pancreatitis. This grant will help the company to acquire market share and enhance the customer base in Europe. The incidence of acute pancreatitis is increasing in many European and Scandinavian countries due to increased alcohol consumption and better diagnostic capability.
Whereas Asia Pacific is expected to be a growing market for Acute Pancreatitis market and expected to grow at a rapid rate. The developing countries such as China and India are leading this market due to the fast growing healthcare sector and large unmet needs over the forecast period. The Middle East & African market especially, the African region is expected to witness a poor growth owing to the lack of knowledge in medical sector, and less development in medical facilities in Middle East & Africa will have limited growth in the market.
Browse Full Report @ https://www.marketresearchfuture.com/reports/acute-pancreatitis-market-1565